Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Key Points: IL-3 receptor α (CD123) expression is elevated in CML progenitor and stem cells compared with healthy donors. CD123 monoclonal antibody targeting represents a novel, potentially clinically relevant approach to deplete CML progenitor and stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Gene expression changes associated with progression and response in chronic myeloid leukemia
Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510423103 · Cited by 583
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · cited 1×
“Nevertheless, LSCs are thought to be insensitive to TKI therapy(6,7) and persist in CML patients, even in those with sustained complete molecular response (CMR).(8,9) This is supported by the observation of molecular relapse after cessation of imatinib in 61% to 66% of CML patients, previously in CMR.”
Background
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Bellavia, D., Raimondo, S., Calabrese, G., Forte, S., Cristaldi, M., Patinella, A., Memeo, L., Manno, M., Raccosta, S., Diana, P., et al. (2017) · Theranostics · doi:10.7150/thno.17092 · Cited by 368
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
“As the IL-3 receptor is overexpressed in chronic myelogenous leukemia (CML) and acute myeloid leukemia blasts [98,99], exosomes derived from these cells loaded with imatinib or BCR-ABL siRNA effectively target and inhibit the growth of CML cells both in vitro and in vivo.”
BackgroundCD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Testa, U., Pelosi, E., & Frankel, A. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-4 · Cited by 255
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154
Metadata
- Authors
- Nievergall, E., Ramshaw, H. S., Yong, A. S. M., Biondo, M., Busfield, S. J., Vairo, G., Lopez, A. F., Hughes, T. P., White, D. L., & Hiwase, D. K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-02-20
- Volume
- 123
- Issue
- 8
- Pages
- 1218-1228
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1971342081
- Cited by
- 98
- References
- 4
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. https://app.cochat.ai/papers/10.1182/blood-2012-12-475194
- The paper
- Nievergall, E., Ramshaw, H. S., Yong, A. S. M., Biondo, M., Busfield, S. J., Vairo, G., Lopez, A. F., Hughes, T. P., White, D. L., & Hiwase, D. K. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. https://doi.org/10.1182/blood-2012-12-475194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.